DashboardAll companies
Run this on your own research
Run this on your own research
Healthcare · Medical Devices

Edwards Lifesciences Corporation

EWNYSE$89.07−$1.02 (−1.13%)Market closed

Price Chart

Daily

Key facts

Market Cap
$51.34B
P/E
48.5x
P/B
5.04x
ROE
10.6%

Edwards Lifesciences Corporation

Healthcare · Medical Devices · FY 2025

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.

CEO
Mr. Bernard J. Zovighian
Employees
15,800

Company Statistics

Valuation

P/E
48.5x
P/B
5.04x
P/S
8.58x
EV/EBITDA
25.4x
P/FCF
39.0x

Margins

Gross
78.0%
EBITDA
32.4%
Operating
27.0%
Pre-Tax
21.0%
Net
17.6%

Returns

ROA
8.0%
ROE
10.6%
ROIC
9.7%

Growth (CAGR)

Rev 3Yr
4.1%
Rev 5Yr
6.7%
Op Inc 3Yr
−2.9%
Net Inc 3Yr
−11.1%

Financial Health

Cash & Cash Equivalents
$2.94B
Net Debt
$421.6M
Debt/Equity
32.5%
Interest Cov
—

Profile

Revenue
$6.07B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Edwards Lifesciences Corporation (EW) Stock Forecast 2026 $89.07 — Price, Financials & Analyst Targets | AlphaLenz